Results 71 to 80 of about 5,159 (106)

Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects. [PDF]

Clin Pharmacol Drug Dev
Gonzalez M, Yang Z, Schelman WR, Zhou X, Gupta N, Chien C.   +5 more
europepmc   +1 more source

Pharmacokinetic drug-drug interaction between the COVID-19 3CL protease inhibitor GST-HG171 and itraconazole in healthy subjects. [PDF]

Antimicrob Agents Chemother
Li X, Li B, Wang M, Wang J, Lu J, Mao J, Zhang T, Tang Y, Yan W, Li C, Zhang G, Ding Y.   +11 more
europepmc   +1 more source

Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies. [PDF]

Clin Pharmacol Drug Dev
Chen Y, Teng R, Szanto A, Kapopara A, Bannerji R, Ogier J, Mahalingam D.   +6 more
europepmc   +1 more source

Assessing Cytochrome P450 Drug Interaction Risk for Dordaviprone Using Physiologically Based Pharmacokinetic Modeling. [PDF]

CPT Pharmacometrics Syst Pharmacol
Jaiswal S, Patel NK, Jones HM, McFeely S, Faison SL, Tippin T, Naderer O.   +6 more
europepmc   +1 more source

Interpretation of Pharmacometabolomics Results: Fingerprint of Drug Exposure or Confounder Effects? Insights from a Urinary Metabolomics Study with Voriconazole in Healthy Participants. [PDF]

Int J Mol Sci
Chobanyan-Jürgens K, Muhareb A, Niesert M, Scherkl C, Meid AD, Cannet C, Pituk D, Hoffmann GF, Stingl JC, Ziegler A, Blank A.   +10 more
europepmc   +1 more source

Managing High-Risk Drug Interactions With Nirmatrelvir/Ritonavir: Experience From a Dedicated Pharmacology Advice Service. [PDF]

Clin Transl Sci
Libiad Y, Franck B, Tron C, Lalanne S, Boglione-Kerrien C, Taïeb F, Verdier MC, Lemaitre F.   +7 more
europepmc   +1 more source

Exploring the roles of cytochrome P450 enzymes and their inhibitors in cancers and non-neoplastic human diseases. [PDF]

Arch Pharm Res
Lee H, Kwon YJ, Chun YJ.
europepmc   +1 more source

Use of a cytochrome P450 humanized mouse model to refine schistosomiasis drug discovery. [PDF]

Proc Natl Acad Sci U S A
Davey SD, Forde-Thomas JE, Hulme BJ, Lees K, Costain AH, Evans M, Rinaldi G, Frame L, Stojanovski L, Simeons FRC, Tavendale A, MacLeod AK, Pichon R, Lee YH, Polak O, Chalmers IW, Dankwa B, Odhiambo BK, Guimaraes VH, Hegarty M, Swain MT, Aubrey W, Caldwell N, MacDonald AS, Gilbert IH, Baragaña B, Read KD, Hoffmann KF.   +27 more
europepmc   +1 more source

Reductive dominance and limited cytochrome P450 activity in neonicotinoid metabolism by elephant liver microsomes. [PDF]

J Vet Med Sci
Watanabe K, Khidkhan K, Saengtienchai A, Somgrid C, Towiboon P, Angkawanish T, Langkaphin W, Namwongprom K, Kittisirik N, Yohannes YB, Ikenaka Y, Nakayama SM, Ishizuka M.   +12 more
europepmc   +1 more source

Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions of Soticlestat as a Victim of CYP Induction and Inhibition, and as a Perpetrator of CYP and P-Glycoprotein Inhibition. [PDF]

Clin Pharmacol Drug Dev
Jia H, Ballard TE, Zhang L, Cohen L, Bergagnini-Kolev MC, Templeton IE, Jones HM, Yin W.   +7 more
europepmc   +1 more source